bluuebunny/crossref_metadata_2025_split huggingface dataset:
GDM
Authors: Wang Kaibo , Ding Xiaoning , Lee Rubao , Kato Shinpei , Zhang Xiaodong 
Published: July 2014

GPGPUs are evolving from dedicated accelerators towards mainstream commodity computing resources. During the transition, the lack of system management of device memory space on GPGPUs has become a major hurdle. In existing GPGPU systems, device memory space is still managed explicitly by individual applications, which not only increases the burden of programmers but can also cause application crashes, hangs, or low performance.
In this paper, we present the design and implementation of GDM, a fully functional GPGPU device memory manager to address the above problems and unleash the computing power of GPGPUs in general-purpose environments. To effectively coordinate the device memory usage of different applications, GDM takes control over device memory allocations and data transfers to and from device memory, leveraging a buffer allocated in each application's virtual memory. GDM utilizes the unique features of GPGPU systems and relies on several effective optimization techniques to guarantee the efficient usage of device memory space and to achieve high performance.
We have evaluated GDM and compared it against state-of-the-art GPGPU system software on a range of workloads. The results show that GDM can prevent applications from crashes, including those induced by device memory leaks, and improve system performance by up to 43%.
Cancer Affects microRNA Expression, Release, and Function in Cardiac and Skeletal Muscle
Authors: Chen Daohong , Goswami Chirayu P. , Burnett Riesa M. , Anjanappa Manjushree , Bhat-Nakshatri Poornima , Muller William , Nakshatri Harikrishna 
Published: July 2014

Abstract
Circulating microRNAs (miRNA) are emerging as important biomarkers of various diseases, including cancer. Intriguingly, circulating levels of several miRNAs are lower in patients with cancer compared with healthy individuals. In this study, we tested the hypothesis that a circulating miRNA might serve as a surrogate of the effects of cancer on miRNA expression or release in distant organs. Here we report that circulating levels of the muscle-enriched miR486 is lower in patients with breast cancer compared with healthy individuals and that this difference is replicated faithfully in MMTV-PyMT and MMTV-Her2 transgenic mouse models of breast cancer. In tumor-bearing mice, levels of miR486 were relatively reduced in muscle, where there was elevated expression of the miR486 target genes PTEN and FOXO1A and dampened signaling through the PI3K/AKT pathway. Skeletal muscle expressed lower levels of the transcription factor MyoD, which controls miR486 expression. Conditioned media (CM) obtained from MMTV-PyMT and MMTV-Her2/Neu tumor cells cultured in vitro were sufficient to elicit reduced levels of miR486 and increased PTEN and FOXO1A expression in C2C12 murine myoblasts. Cytokine analysis implicated tumor necrosis factor α (TNFα) and four additional cytokines as mediators of miR486 expression in CM-treated cells. Because miR486 is a potent modulator of PI3K/AKT signaling and the muscle-enriched transcription factor network in cardiac/skeletal muscle, our findings implicated TNFα-dependent miRNA circuitry in muscle differentiation and survival pathways in cancer. Cancer Res; 74(16); 4270–81. ©2014 AACR.
miR-21 Induces Myofibroblast Differentiation and Promotes the Malignant Progression of Breast Phyllodes Tumors
Authors: Gong Chang , Nie Yan , Qu Shaohua , Liao Jian-You , Cui Xiuying , Yao Herui , Zeng Yunjie , Su Fengxi , Song Erwei , Liu Qiang 
Published: July 2014

Abstract
Phyllodes tumors of breast, even histologically diagnosed as benign, can recur locally and have metastatic potential. Histologic markers only have limited value in predicting the clinical behavior of phyllodes tumors. It remains unknown what drives the malignant progression of phyllodes tumors. We found that the expression of myofibroblast markers, α-smooth muscle actin (α-SMA), fibroblast activation protein (FAP), and stromal cell–derived factor-1 (SDF-1), is progressively increased in the malignant progression of phyllodes tumors. Microarray showed that miR-21 was one of the most significantly upregulated microRNAs in malignant phyllodes tumors compared with benign phyllodes tumors. In addition, increased miR-21 expression was primarily localized to α-SMA–positive myofibroblasts. More importantly, α-SMA and miR-21 are independent predictors of recurrence and metastasis, with their predictive value of recurrence better than histologic grading. Furthermore, miR-21 mimics promoted, whereas miR-21 antisense oligos inhibited, the expression of α-SMA, FAP, and SDF-1, as well as the proliferation and invasion of primary stromal cells of phyllodes tumors. The ability of miR-21 to induce myofibroblast differentiation was mediated by its regulation on Smad7 and PTEN, which regulate the migration and proliferation, respectively. In breast phyllodes tumor xenografts, miR-21 accelerated tumor growth, induced myofibroblast differentiation, and promoted metastasis. This study suggests an important role of myofibroblast differentiation in the malignant progression of phyllodes tumors that is driven by increased miR-21. Cancer Res; 74(16); 4341–52. ©2014 AACR.
EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein
Authors: Hristodorov Dmitrij , Amoury Manal , Mladenov Radoslav , Niesen Judith , Arens Katharina , Berges Nina , Hein Lea , Di Fiore Stefano , Pham Anh-Tuan , Huhn Michael , Helfrich Wijnand , Fischer Rainer , Thepen Theo , Barth Stefan 
Published: July 2014

Abstract
In normal epithelia, the epithelial cell adhesion molecule (EpCAM) expression is relatively low and only present at the basolateral cell surface. In contrast, EpCAM is aberrantly overexpressed in various human carcinomas. Therefore, EpCAM is considered to be a highly promising target for antibody-based cancer immunotherapy. Here, we present a new and fully human cytolytic fusion protein (CFP), designated “anti–EpCAM(scFv)-MAP,” that is comprised of an EpCAM-specific antibody fragment (scFv) genetically fused to the microtubule-associated protein tau (MAP). Anti–EpCAM(scFv)-MAP shows potent EpCAM-restricted proapoptotic activity toward rapidly proliferating carcinoma cells. In vitro assays confirmed that treatment with anti–EpCAM(scFv)-MAP resulted in the colocalization and stabilization of microtubules, suggesting that this could be the potential mode of action. Dose-finding experiments indicated that anti–EpCAM(scFv)-MAP is well tolerated in mice. Using noninvasive far-red in vivo imaging in a tumor xenograft mouse model, we further demonstrated that anti–EpCAM(scFv)-MAP inhibited tumor growth in vivo. In conclusion, our data suggest that anti–EpCAM(scFv)-MAP may be of therapeutic value for the targeted elimination of EpCAM+ carcinomas. Mol Cancer Ther; 13(9); 2194–202. ©2014 AACR.
Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
Authors: Huck Jessica J. , Zhang Mengkun , Mettetal Jerome , Chakravarty Arijit , Venkatakrishnan Karthik , Zhou Xiaofei , Kleinfield Rob , Hyer Marc L. , Kannan Karuppiah , Shinde Vaishali , Dorner Andy , Manfredi Mark G. , Shyu Wen Chyi , Ecsedy Jeffrey A. 
Published: July 2014

Abstract
Aurora A kinase orchestrates multiple key activities, allowing cells to transit successfully into and through mitosis. MLN8237 (alisertib) is a selective Aurora A inhibitor that is being evaluated as an anticancer agent in multiple solid tumors and heme-lymphatic malignancies. The antitumor activity of MLN8237 when combined with docetaxel or paclitaxel was evaluated in in vivo models of triple-negative breast cancer grown in immunocompromised mice. Additive and synergistic antitumor activity occurred at multiple doses of MLN8237 and taxanes. Moreover, significant tumor growth delay relative to the single agents was achieved after discontinuing treatment; notably, durable complete responses were observed in some mice. The tumor growth inhibition data generated with multiple dose levels of MLN8237 and paclitaxel were used to generate an exposure–efficacy model. Exposures of MLN8237 and paclitaxel achieved in patients were mapped onto the model after correcting for mouse-to-human variation in plasma protein binding and maximum tolerated exposures. This allowed rank ordering of various combination doses of MLN8237 and paclitaxel to predict which pair would lead to the greatest antitumor activity in clinical studies. The model predicted that 60 and 80 mg/m2 of paclitaxel (every week) in patients lead to similar levels of efficacy, consistent with clinical observations in some cancer indications. The model also supported using the highest dose of MLN8237 that can be achieved, regardless of whether it is combined with 60 or 80 mg/m2 of paciltaxel. The modeling approaches applied in these studies can be used to guide dose-schedule optimization for combination therapies using other therapeutic agents. Mol Cancer Ther; 13(9); 2170–83. ©2014 AACR.
Pistachio Nut Consumption Modifies Systemic Hemodynamics, Increases Heart Rate Variability, and Reduces Ambulatory Blood Pressure in Well‐Controlled Type 2 Diabetes: a Randomized Trial
Authors: Sauder Katherine A. , McCrea Cindy E. , Ulbrecht Jan S. , Kris‐Etherton Penny M. , West Sheila G. 
Published: July 2014

Background

Managing cardiovascular risk factors is important for reducing vascular complications in type 2 diabetes, even in individuals who have achieved glycemic control. Nut consumption is associated with reduced cardiovascular risk; however, there is mixed evidence about the effect of nuts on blood pressure (
BP
), and limited research on the underlying hemodynamics. This study assessed the effect of pistachio consumption on
BP
, systemic hemodynamics, and heart rate variability in adults with well‐controlled type 2 diabetes.

Methods and Results

We enrolled 30 adults (40 to 74 years) with type 2 diabetes in a randomized, crossover, controlled feeding study. After a 2‐week run‐in period, participants consumed a low‐fat control diet (27% fat) containing low‐fat/high‐carbohydrate snacks and a moderate‐fat diet (33% fat) containing pistachios (20% of total energy) for 4 weeks each, separated by a 2‐week washout. Following each diet period, we assessed
BP
, systemic hemodynamics, and heart rate variability at rest and during acute mental stress, and, in a subset of participants (n=21), 24‐hour ambulatory
BP
.
BP
at rest and during stress did not differ between treatments. The pistachio diet significantly reduced total peripheral resistance (−3.7±2.9%,
P
=0.004), increased cardiac output (3.1±2.3%,
P
=0.002), and improved some measures of heart rate variability (all
P
<0.05). Systolic ambulatory
BP
was significantly reduced by 3.5±2.2 mm Hg (
P
=0.046) following the pistachio diet, with the greatest reduction observed during sleep (−5.7±2.6 mm Hg,
P
=0.052).

Conclusions
A moderate‐fat diet containing pistachios modestly improves some cardiovascular risk factors in adults with well‐controlled type 2 diabetes.

Clinical Trial Registration

URL:
www.clinicaltrials.gov
. Unique identifier: NCT00956735.
A new species of Neoliomera Odhner, 1925, from the western Pacific, and the first record of N. demani Forest &amp; Guinot, 1961, from Taiwan (Crustacea: Decapoda: Brachyura: Xanthidae)
Authors: HO P.-H. , NG PETER K. L. 
Published: July 2014

A new species of a strikingly coloured xanthid crab of the genus Neoliomera Odhner, 1925, is described from coral reefs in Guam, Taiwan, and the Hawaiian Islands. The new species is allied to N. pubescens (H. Milne Edwards, 1834), and N. demani Forest & Guinot, 1961, but differs in the form of the carapace armature, frontal margin, structure of the chela, proportions of the ambulatory merus and the form of the male first gonopod. Neoliomera demani is also recorded from Taiwan for the first time and aspects of its taxonomy are discussed.
Longitudinal sex differences of externalising and internalising depression symptom trajectories: Implications for assessment of depression in men from an online study
Authors: Rice Simon M , Fallon Barry J , Aucote Helen M , Möller-Leimkühler AnneMaria , Treeby Matt S , Amminger G Paul 
Published: July 2014

Background: Clinical reports indicate that men tend to engage in a range of externalising behaviours in response to negative emotional states. Such externalising behaviours have been theorised to reflect a male sub-type of depression that is inconsistent with current diagnostic criteria, resulting in impeded detection and treatment rates of depressed men. Aims: In addressing previous study design limitations, this article presents self-report longitudinal data for the multidimensional Male Depression Risk Scale (MDRS-22) against ratings of diagnostic criteria for major depressive disorder as assessed by the Patient Health Questionnaire–Depression Module (PHQ-9). Longitudinal psychometric properties of the MDRS-22 are reported and symptom trajectories described. Method: A sample of 233 adults (males = 125; 54%) completed measures of externalising and prototypic depression symptoms at Time 1, and again at Time 2 (15 weeks later). Psychometric properties were examined and within-subjects analyses undertaken. Results: The MDRS-22 demonstrated stable internal consistency and test–retest correlations equivalent to those observed for the PHQ-9. Both prototypic and externalising depression symptoms increased with experiences of recent negative life events. Marked gender differences were observed. Males experiencing ≥ 2 stressful negative life events reported significantly higher MDRS-22 scores at both Time 1 and Time 2 relative to comparable females. Conclusion: Findings contribute to the validity of the MDRS-22 as a measure of externalising depression symptoms. Results suggest that while both males and females experience externalising depression symptoms, these symptoms may be particularly elevated for men following experiences of negative life events. Findings suggest that externalising symptoms may be a special feature of depression for men. Given the problematic nature of such externalising symptoms (e.g. excessive substance use, aggression, risk-taking), their clinical assessment appears warranted.
A whole-population profile of HPV testing as a test of cure for high-grade cervical dysplasia in NSW, Australia
Authors: Morrell Stephen , Qian Liping 
Published: July 2014

Introduction Few population-based studies have been conducted on the efficacy of human papilloma virus (HPV) testing as a test of cure for high grade cervical dysplasia. Methods A cohort of women (n = 11,521) with high grade (CIN2+) cervical dysplasia diagnosed during 2006–2010, who also had accompanying HPV testing (n = 19,434 HPV tests), was analyzed with respect to National Health and Medical Research Council (NHMRC) follow-up guidelines. Cure rates, and number of follow-up tests and times to reach a cure were estimated. Results In the ≥2-years following high grade dysplasia, 53% of women had a single follow-up HPV test, 33% had two, and 14% had three or more HPV follow-up tests. 75% of women with follow-up HPV and cytology testing according to NHMRC guidelines were cured (2,210 from 2,948). Cure rates were lowest in those aged <30 (71%) and highest in women aged 30–49 (80%). Of those cured, 68% attained cure by the second HPV test, 21% by the third, and 11% at the fourth or later HPV test. The median time to cure was 1,097 days. In non-cured women, 56% of test results originated from all-negative cytology with positive HPV, compared with 9% from all-negative HPV results. Conclusions Cure rates in women with follow-up testing according to NHMRC guidelines are high. Further studies are needed of the high proportion of women with negative cytology classed as not cured due to HPV positivity, and of the high proportion of women with high grade dysplasia who had one follow-up HPV test only.
Cost-effectiveness of health research study participant recruitment strategies: A systematic review
Authors: Huynh Lynn , Johns Benjamin , Liu Su-Hsun , Vedula S Swaroop , Li Tianjing , Puhan Milo A 
Published: July 2014

Background: A large fraction of the cost of conducting clinical trials is allocated to recruitment of participants. A synthesis of findings from studies that evaluate the cost and effectiveness of different recruitment strategies will inform investigators in designing cost-efficient clinical trials. Purpose: To systematically identify, assess, and synthesize evidence from published comparisons of the cost and yield of strategies for recruitment of participants to health research studies. Methods: We included randomized studies in which two or more strategies for recruitment of participants had been compared. We focused our economic evaluation on studies that randomized participants to different recruitment strategies. Results: We identified 10 randomized studies that compared recruitment strategies, including monetary incentives (cash or prize), direct contact (letters or telephone call), and medical referral strategies. Only two of the 10 studies compared strategies for recruiting participants to clinical trials. We found that allocating additional resources to recruit participants using monetary incentives or direct contact yielded between 4% and 23% additional participants compared to using neither strategy. For medical referral, recruitment of prostate cancer patients by nurses was cost-saving compared to recruitment by consultant urologists. For all underlying study designs, monetary incentives cost more than direct contact with potential participants, with a median incremental cost per recruitment ratio of Int$72 (Int$—International dollar, a theoretical unit of currency) for monetary incentive strategy compared to Int$28 for direct contact strategy. Only monetary incentives and source of referral were evaluated for recruiting participants into clinical trials. Limitations: We did not review studies that presented non-monetary cost or lost opportunity cost. We did not adjust for the number of study recruitment sites or the study duration in our economic evaluation analysis. Conclusions: Systematic and explicit reporting of cost and effectiveness of recruitment strategies from randomized comparisons is required to aid investigators to select cost-efficient strategies for recruiting participants to health research studies including clinical trials.
Tetramer‐visualized gluten‐specific CD4+ T cells in blood as a potential diagnostic marker for coeliac disease without oral gluten challenge
Authors: Christophersen Asbjørn , Ráki Melinda , Bergseng Elin , Lundin Knut EA , Jahnsen Jørgen , Sollid Ludvig M , Qiao Shuo-Wang 
Published: July 2014

BackgroundDiagnosing coeliac disease (CD) can be challenging, despite highly specific autoantibodies and typical mucosal changes in the small intestine. The T‐cell response to gluten is a hallmark of the disease that has been hitherto unexploited in clinical work‐up.ObjectivesWe aimed to develop a new method that directly visualizes and characterizes gluten‐reactive CD4+ T cells in blood, independently of gluten challenge, and to explore its diagnostic potential.MethodsWe performed bead‐enrichment of DQ2.5‐glia‐α1a and DQ2.5‐glia‐α2 tetramer+ cells in the blood of control individuals, treated (TCD) and untreated patients (UCD). We visualized these cells by flow cytometry, sorted them and cloned them. We assessed their specificity by antigen stimulation and re‐staining with tetramers.ResultsWe detected significantly more gliadin‐tetramer+ CD4+ effector memory T cells (TEM) in UCD and TCD patients, compared to controls. Significantly more gliadin‐tetramer+ TEM in the CD patients than in controls expressed the gut‐homing marker integrin‐β7.ConclusionQuantification of gut‐homing, gluten‐specific TEM in peripheral blood, visualized with human leukocyte antigen (HLA) ‐tetramers, may be used to distinguish CD patients from healthy individuals. Easy access to gluten‐reactive blood T cells from diseased and healthy individuals may lead to new insights on the disease‐driving CD4+ T cells in CD.
Diagnostic impact of routine colonoscopy following acute diverticulitis: A multicenter study in 808 patients and controls
Authors: Lecleire Stéphane , Nahon Stéphane , Alatawi Abdullah , Antonietti Michel , Chaput Ulriikka , Di-Fiore Aude , Alhameedi Raied , Marteau Philippe , Ducrotté Philippe , Dray Xavier 
Published: July 2014

BackgroundThe diagnosis of acute diverticulitis is mainly based on clinical, biological and computed tomography (CT)‐scan findings. Elective colonoscopy is recommended after medical treatment, to rule out another diagnosis and to detect associated conditions; however, the relevance of this recommendation has been questioned.Patients and methodsBetween January 2005 and December 2011, we retrospectively identified in three referral centers the consecutive patients whom underwent a colonoscopy after the medical treatment of a CT scan‐proven acute diverticulitis episode. We excluded from the analysis patients with haematochezia or recent change in bowel habits. Sex and age‐matched asymptomatic patients undergoing a screening colonoscopy were chosen as a control group. We collected and compared the results of colonoscopy and histological findings in both groups.ResultsWe matched 404 patients whom underwent a colonoscopy after an episode of acute diverticulitis with 404 control patients. Their mean age was 60.9 years, with 59% being women. Colorectal adenoma, advanced adenoma and cancer detection rates in acute diverticulitis patients were 12.1%, 2.7% and 0.25%, respectively; versus 14.6% (p  = 0.35), 6.7% (p  = 0.01) and 0.25% respectively, in control patients.ConclusionsDiagnosis rates for adenomas and for colorectal cancer during a colonoscopy scheduled after acute diverticulitis were similar than those of control patients undergoing a screening colonoscopy, while the detection rate of advanced adenomas was lower. We suggest that colonoscopy should be indicated only in selected patients, i.e. those presenting with reasonable doubt on initial CT‐scan, those with alarm symptoms, and those with identified risk factors for colorectal cancer.